NCT04772989: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase; Patients may have received up to 5 prior anti-cancer therapies and an unlimited number of prior hormonal therapies
Exclusions: Patients with prior treatment of an anti-TIGIT antibody

Comments are closed.

Up ↑